Consolidated statement of income
for the year ended December 31
|
|
|
|
|
|
|
Millions of euros |
Note |
|
2007 |
|
20061 |
|
Continuing operations |
|
|
|
|
|
|
Revenue |
|
|
10,217 |
|
10,023 |
|
Cost of sales |
|
|
(6,252) |
|
(6,224) |
|
Gross profit |
|
|
3,965 |
|
3,799 |
|
|
|
|
|
|
|
Selling expenses |
|
(2,230) |
|
(2,203) |
|
|
Research and development expenses |
|
(282) |
|
(280) |
|
|
General and administrative expenses |
|
(654) |
|
(636) |
|
|
Other operating income/(expenses) |
(52) |
|
179 |
|
|
|
|
|
(3,218) |
|
(2,940) |
|
Operating income |
|
|
747 |
|
859 |
|
|
|
|
|
|
|
Financing income |
|
157 |
|
123 |
|
|
Financing expenses |
|
(277) |
|
(229) |
|
|
|
|
|
|
|
|
Operating income less financing income and expenses |
|
|
627 |
|
753 |
|
Results from associates and joint ventures |
|
(20) |
|
87 |
|
|
Profit before tax |
|
|
607 |
|
840 |
|
|
|
|
|
|
|
Income tax |
|
(166) |
|
(96) |
|
|
Profit for the period from continuing operations |
|
|
441 |
|
744 |
|
|
|
|
|
|
|
Discontinued operations |
|
|
|
|
|
|
Profit for the period from discontinued operations (Organon BioSciences) |
|
8,920 |
|
438 |
|
|
Profit for the period |
|
|
9,361 |
|
1,182 |
|
|
|
|
|
|
|
Attributable to: |
|
|
|
|
|
|
– Equity holders of the company |
|
|
9,330 |
|
1,153 |
|
– Minority interests |
|
|
31 |
|
29 |
|
Profit for the period |
|
|
9,361 |
|
1,182 |
|
|
|
|
|
|
|
Earnings per share, in euros |
|
|
|
|
|
|
Continuing operations: |
|
|
|
|
|
|
– Basic |
|
|
1.49 |
|
2.49 |
|
– Diluted |
|
|
1.47 |
|
2.48 |
|
Discontinued operations: |
|
|
|
|
|
|
– Basic |
|
|
32.33 |
|
1.53 |
|
– Diluted |
|
|
32.08 |
|
1.52 |
|
Total operations: |
|
|
|
|
|
|
– Basic |
|
|
33.82 |
|
4.02 |
|
– Diluted |
|
|
33.55 |
|
4.00 |
|
|||||
 |
|||||
